Home › Funds › TRV GP VI, LLC › RAPP
TRV GP VI, LLC position in RAPP
RAPPORT THERAPEUTICS INC · Health Care
TRV GP VI, LLC reported holding 969,218 shares of RAPP (RAPPORT THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$40.4M, representing 17.39% of its reported portfolio and ranking #3 among its reported holdings. TRV GP VI, LLC has disclosed RAPP holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How TRV GP VI, LLC's RAPP position evolved
TRV GP VI, LLC first disclosed a stake in RAPP in Q4 2024 at 969,218 shares (US$17.2M). The position peaked in Q2 2026 at 969,218 shares, worth US$40.4M. Across 7 filings, TRV GP VI, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 969,218 shares valued at US$40.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 969.22K | $17.19M | New |
| Q1 2025 | 969.22K | $9.72M | Hold |
| Q2 2025 | 969.22K | $11.02M | Hold |
| Q3 2025 | 969.22K | $28.79M | Hold |
| Q4 2025 | 969.22K | $29.41M | Hold |
| Q1 2026 | 969.22K | $30.33M | Hold |
| Q2 2026 | 969.22K | $40.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RAPP and 13F data
RAPP (RAPPORT THERAPEUTICS INC) is a Health Care company. 66 other funds we track also report a position in RAPP — the largest reported positions include TRV GP V, LLC (US$261.7M), ARCH Venture Management, LLC (US$155.4M), Cormorant Asset Management, LP (US$110.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RAPP
- TRV GP V, LLC 6.28M sh · $261.71M · Q2 2026
- ARCH Venture Management, LLC 3.73M sh · $155.38M · Q2 2026
- Cormorant Asset Management, LP 2.66M sh · $110.74M · Q2 2026
- Sofinnova Investments, Inc. 1.90M sh · $79.36M · Q2 2026
- JOHNSON & JOHNSON 1.78M sh · $74.36M · Q2 2026
- BAKER BROS. ADVISORS LP 1.55M sh · $64.47M · Q2 2026
- PERCEPTIVE ADVISORS LLC 773.34K sh · $32.23M · Q2 2026
- Vestal Point Capital, LP 730.00K sh · $30.42M · Q2 2026
- Siren, L.L.C. 641.47K sh · $26.73M · Q2 2026
- Sio Capital Management, LLC 307.66K sh · $12.82M · Q2 2026
- Burkehill Global Management, LP 250.00K sh · $10.42M · Q2 2026
- Artia Global Partners LP 138.51K sh · $5.77M · Q2 2026
More on TRV GP VI, LLC
FAQ
How long has TRV GP VI, LLC held RAPP?
TRV GP VI, LLC has disclosed RAPP holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is TRV GP VI, LLC's current position in RAPP?
As of Q2 2026, TRV GP VI, LLC holds 969.22K shares of RAPP (RAPPORT THERAPEUTICS INC), valued at $40.39M, representing 17.39% of its reported portfolio and ranking #3.
Has TRV GP VI, LLC been buying or selling RAPP?
In the latest 13F filing (Q2 2026), TRV GP VI, LLC held unchanged its position in RAPP. The position peaked in Q2 2026 at 969.22K shares.
Which other funds hold RAPP?
Other major institutional holders of RAPP include TRV GP V, LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.